ARDT at a glance
Ardent Health, Inc. (ARDT, SEC CIK 1756655) filed its latest 10-K annual report on March 16, 2026, a 10-Q quarterly report on August 10, 2026, an 8-K current report on September 4, 2026 and Form 4 insider filings as recently as September 29, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Ardent Health, Inc. (ARDT) reported revenue of $6.3 billion (up 6.0% from FY2024) and net income of $135.8 million. Diluted EPS was $0.96.
- As of June 30, 2026, 28 institutional investment managers tracked by SignalX reported holding Ardent Health, Inc. (ARDT) shares worth $191.2 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by DeMichiei Robert on June 5, 2026 of 11,260 shares at $8.73 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $6.3B
- +6.0% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 28 funds
- $191.2M · +3 vs prior quarter
- Latest 8-K
- Sep 4, 2026
- Item 8.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Quarterly revenue decreased $23.0M, or 1.4% YoY, driven by lower revenue per adjusted admission
- Adjusted admissions increased 2.5%, while admissions declined 1.0% and surgeries declined 2.9%
- Revenue per adjusted admission decreased 3.9%, including a $57.8M decline in Medicaid supplemental payments
- Medicaid supplemental-payment revenue decreased to $197.1M from $254.9M YoY
- Near-term headwinds: OBBBA Medicaid reductions, expiring ACA subsidies, labor shortages, inflation, and reimbursement pressure
Risk Factors
- No material changes to previously disclosed risk factors from the Annual Report
- Regulatory and compliance risks remain those incorporated from the Annual Report
- Operational and competitive risks remain unchanged from the Annual Report
- Financial risks remain unchanged from the Annual Report
- Stock repurchase authorization $33.7 million remaining as of June 30, 2026
AI summary of the ARDT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- Prior-period Adjusted EBITDA reduced by $97.7M after removing two Q3 2025 non-GAAP adjustments
- 2025 Adjusted EBITDA revised to $447.3M from $545.0M, reducing reported operating-performance metrics
Item EX-99.1: Item EX-99.1
- Revised 2025 Form 10-K MD&A clarifies definitions and reconciliations for Adjusted EBITDA and Adjusted EBITDAR
- 2025 Adjusted EBITDA $447.3M, down from $498.5M in 2024 despite $39.3M equity-based compensation addback
Item 2.02: Results of Operations and Financial Condition
- Reg FD liability protection language; no operating results included in the provided excerpt
- No revenue, earnings, guidance, or fiscal-year 2026 performance figures available for investor assessment
Item EX-99.1: Item EX-99.1
- Q2 revenue $1.62B, down 1.4% YoY, reflecting lower reimbursement and delayed New Mexico payment benefits
- Net income fell to $17M from $73M, while adjusted EBITDA declined 32.3% to $115M
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Former CEO Martin J. Bonick’s departure and Board resignation effective June 2, 2026
- Separation agreement provides severance consistent with Company termination without “Cause”
AI summaries of ARDT 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ARDT
Don't miss the next ARDT filing
- Alerts as it files. A push when ARDT files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ARDT, by share count.
- Ask anything. An AI agent that reads every ARDT filing and answers with sources.
ARDT alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| LUMSDAINE ALFRED | F | Sep 25, 2026 | 3,389 | $10.54 |
| Petrovich Stephen C. | F | Sep 25, 2026 | 788 | $10.54 |
| Byers David Raynor | F | Sep 25, 2026 | 524 | $10.54 |
| Caspers Dave | A | Jul 1, 2026 | 103,653 | - |
| DeMichiei Robert | Buy | Jun 5, 2026 | 11,260 | $8.73 |
| LUMSDAINE ALFRED | Buy | Jun 5, 2026 | 10,000 | $8.81 |
| Havdala Ellen | A | Apr 1, 2026 | 14,231 | - |
| LUMSDAINE ALFRED | A | Apr 1, 2026 | 53,846 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | $5.4B | $6.0B | $6.3B | |
| Net Income | $53.9M | $210.3M | $135.8M | |
| Net Margin | 1.0% | 3.5% | 2.1% | |
| Balance Sheet | ||||
| Total Assets | $4.7B | $5.0B | $5.3B | |
| Equity | $670.9M | $1.1B | $1.3B | |
| ROE | 8.0% | 18.6% | 10.5% | |
| Per Share | ||||
| EPS | $0.43 | $1.58 | $0.96 | |
| Cash Flow | ||||
| Operating CF | $221.7M | $315.0M | $470.5M | |
Source: XBRL data in Ardent Health, Inc. (ARDT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate ARDT share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 28 | $191.2M |
| Q1 2026 | 25 | $154.3M |
| Q4 2025 | 23 | $161.9M |
| Q3 2025 | 23 | $248.8M |
| Q2 2025 | 24 | $120.5M |
| Q1 2025 | 18 | $90.6M |
| Q4 2024 | 13 | $231.7M |
| Q3 2024 | 9 | $76.2M |
- AQR Capital Management+505.5K (+54%)
- BlackRock+418.1K (+24%)
- Ameriprise Financial+333.9K (+19%)
- Goldman Sachs Group+85.4K (+39%)
- JPMorgan Chase & Co+73.7K (+44%)
- Two Sigma Investments−189.5K (-77%)
- Vanguard Portfolio Management LLC−71.4K (-26%)
- Citadel Advisors LLC−55.4K (-33%)
- Vanguard Capital Management LLC−44.6K (-4%)
- State Street Corp−19.9K (-3%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 163 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ARDT filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 29, 2026 | - | - | - |
| 4 | Sep 29, 2026 | - | - | - |
| 4 | Sep 29, 2026 | - | - | - |
| 8-K | Sep 4, 2026 | - | Analysis | - |
| 10-Q | Aug 10, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 4, 2026 | - | Analysis | - |
| 4 | Jul 2, 2026 | - | - | - |
| 8-K | Jun 30, 2026 | - | Analysis | - |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 8-K | Jun 2, 2026 | - | Analysis | |
| 8-K | May 26, 2026 | - | Analysis | |
| 10-Q | May 6, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 5, 2026 | - | Analysis | - |
| 4 | Apr 2, 2026 | - | - | - |
| 4 | Apr 2, 2026 | - | - | - |
| 4 | Apr 2, 2026 | - | - | - |
| 4 | Apr 2, 2026 | - | - | - |
| 4 | Apr 2, 2026 | - | - | - |
| 4 | Apr 2, 2026 | - | - | - |
| 4 | Apr 2, 2026 | - | - | - |
| 4 | Apr 2, 2026 | - | - | - |
| 4 | Apr 2, 2026 | - | - | - |
| 4 | Apr 2, 2026 | - | - | - |
| 4 | Apr 2, 2026 | - | - | - |
Related Health Care companies
- CYH · COMMUNITY HEALTH SYSTEMS INCServices-General Medical & Surgical Hospitals, NEC
- HCA · HCA HealthcareServices-General Medical & Surgical Hospitals, NEC
- SGRY · Surgery Partners, Inc.Services-General Medical & Surgical Hospitals, NEC
- UHS · Universal Health ServicesServices-General Medical & Surgical Hospitals, NEC
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
ARDT SEC filings: frequently asked questions
Which institutions hold ARDT stock?
As of June 30, 2026, the largest Ardent Health, Inc. (ARDT) holders among the 13F filers tracked by SignalX were Ventas ($91.9 million), BlackRock ($21.4 million), Ameriprise Financial ($20.8 million), AQR Capital Management ($14.2 million), Vanguard Capital Management LLC ($9.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ARDT's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Ardent Health, Inc. (ARDT) reported revenue of $6.3 billion (up 6.0% from FY2024) and net income of $135.8 million. Diluted EPS was $0.96. The figures come from the XBRL data in the 10-K.
What did ARDT report in its latest 8-K?
Ardent Health, Inc. (ARDT) filed an 8-K on September 4, 2026 reporting Item 8.01 (Other Events). Prior-period Adjusted EBITDA reduced by $97.7M after removing two Q3 2025 non-GAAP adjustments.
What are the latest ARDT SEC filings?
Ardent Health, Inc. (ARDT) filed its latest 10-K annual report on March 16, 2026, a 10-Q quarterly report on August 10, 2026, an 8-K current report on September 4, 2026 and a Form 4 insider filing on September 29, 2026.
What is ARDT's SEC CIK number?
Ardent Health, Inc. (ARDT)'s SEC Central Index Key (CIK) is 1756655. EDGAR lists every ARDT filing under that number.
Ask anything about ARDT
The research agent reads ARDT's filings, financials, insider trades and 13F holders, then answers with sources.